MILFORD, Massachusetts, USA – June 8, 2026
Waters Corporation has introduced its BioResolve™ Peptide and GTxResolve™ Lipid Phenyl-Hexyl+ and C18+ Columns, an industry-first reversed-phase bioseparation platform designed to accelerate the characterization of GLP-1 therapeutics, insulin products, and lipid nanoparticles (LNPs). Announced during the 55th International Symposium on High Performance Liquid Phase Separations and Related Techniques, the innovative technology addresses one of the most significant challenges facing modern biopharmaceutical development: the reliable identification and separation of structurally similar impurities that can impact product quality, manufacturing efficiency, regulatory compliance, and patient safety. According to Waters, the new platform delivers up to three times faster GLP-1 characterization and up to two times faster lipid nanoparticle component analysis, enabling scientists to streamline analytical workflows, shorten development timelines, and accelerate the delivery of next-generation therapies. As demand continues to surge for obesity medicines, peptide therapeutics, mRNA-based medicines, and advanced biologics, the launch positions Waters at the forefront of analytical innovation supporting the evolving needs of the global life sciences industry.
Accelerating GLP-1 and Peptide Therapeutic Development
The rapid growth of GLP-1 receptor agonists, insulin analogs, and peptide-based medicines has increased demand for analytical technologies capable of detecting and resolving highly complex impurities. Many peptide-related impurities differ by only a single atom or subtle structural variations, making them exceptionally difficult to characterize using conventional reversed-phase chromatography methods. Waters developed the BioResolve™ Peptide Columns specifically to address these challenges through advanced surface chemistry and optimized superficially porous particle technology. The company reports that the columns provide up to two times greater resolving power and sensitivity, enabling researchers to identify and track low-level impurities more effectively while maintaining significantly shorter run times.
Enhanced resolution and reproducibility can help pharmaceutical developers generate higher-quality analytical data, simplify method development, and support increasingly stringent regulatory requirements. By reducing analytical bottlenecks and improving confidence in molecular characterization, the platform may play a critical role in accelerating the development of new obesity, diabetes, and metabolic disease treatments.
Advanced Lipid Nanoparticle Analysis Supports mRNA Innovation
Advertisement
The newly launched GTxResolve™ Lipid Columns were engineered to improve analytical performance for lipid nanoparticles, which have become essential delivery systems for mRNA vaccines, gene therapies, and emerging cell-based medicines. Lipid nanoparticle formulations often contain complex mixtures of ionizable lipids and excipients that require highly specialized separation techniques to ensure product quality and consistency. Waters reports that the platform delivers up to two times faster LNP component analysis, while improving peak shape, selectivity, and impurity resolution. Proprietary charged-surface chemistry helps reduce peak tailing and improve separation efficiency, while large-pore particle architecture enables effective analysis across a broad range of lipid species.
The technology is compatible with multiple detection platforms, including mass spectrometry, ultraviolet detection, charged aerosol detection, and evaporative light scattering detection, providing flexibility across research, development, and manufacturing environments. As pharmaceutical companies continue investing in mRNA therapeutics and precision medicine technologies, advanced lipid analytics are becoming increasingly important for regulatory readiness and commercial success.
Delivering Regulatory-Ready Data for Next-Generation Biologics
Waters emphasized that the BioResolve™ Peptide and GTxResolve™ Lipid Columns are the first chromatography columns in its portfolio specifically quality-control batch tested for GLP-1 analysis and lipid nanoparticle applications, addressing a longstanding challenge for biopharmaceutical manufacturers. The combination of innovative chemistry, particle engineering, and application-specific validation is designed to deliver reproducible analytical performance from early-stage discovery through commercial manufacturing. By improving impurity detection, reducing method redevelopment, and accelerating analytical workflows, the platform has the potential to lower development costs while enhancing regulatory preparedness.
Industry experts believe the increasing complexity of biologics, peptide medicines, and nucleic acid-based therapies will continue driving demand for high-resolution analytical technologies capable of supporting quality, safety, and compliance. With the introduction of this industry-first bioseparation platform, Waters is strengthening its position as a key technology partner helping life sciences organizations bring innovative therapies to patients more efficiently and with greater confidence.
Source: Waters Corporation press release
